An observational study in Progressive Supranuclear Palsy- Richardson Syndrome (PSP-R), sponsored by SYSNAV. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by SYSNAV · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Supranuclear Palsy, Progressive with a site in France — 6 open to participants now, 6 under way, 1 of them phase 3. Supranuclear Palsy, Progressive · France.
Among the 22 studies in Supranuclear Palsy, Progressive with a site in France, this one is the only one that started in 2027, is one of 6 observational ones, and was the 20th registered.
171 studies on the registry are indexed under Supranuclear Palsy, Progressive; 51 are open to participants now.
Browse Supranuclear Palsy, Progressive studies →6 of the 22 studies in Supranuclear Palsy, Progressive with a site in France are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in France, United States, Australia and 9 more countries
Ages 41–81
Assistance Publique Hopitaux De Marseille · Sites in France
Ages 18+ · Healthy volunteers
University Hospital, Bordeaux · Sites in France
Ages 18+
Nantes University Hospital · Sites in France
Ages 40–89
Assistance Publique Hopitaux De Marseille · Sites in France
Ages 40–80 · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 38 Supranuclear Palsy, Progressive studies recruiting now, 22 (58%) set no upper age limit and 2 (5%) stop at 75 or younger; 5 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 8 · Phase 3 5
First in 2006; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 200 across 66 observational studies indexed under Supranuclear Palsy, Progressive.
Median enrollment 130 across the 16 interventional studies, 150 across the 6 observational. Of the 15 that completed or were terminated, 3 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 22 have an industry lead sponsor. The 10 most frequent:
SYSNAV is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
SYSNAV has 1 study filed under Supranuclear Palsy, Progressive — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 22 studies in Supranuclear Palsy, Progressive with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aims to assess the feasibility/acceptability of real-world activity monitoring by the Syde® wearable device in PSP-R. The Syde® collected data will be compared to on-site conventional clinical endpoints, including functional capacity and cognitive assessments, as well as core scales assessments.
Patients With Progressive Supranuclear Palsy - Richardson Syndrome (PSP-R)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1.18 years old or older
2.Participants affiliated to, or beneficiary from, a social security.
3.Ambulant patients (i.e. able to walk 10 meters without assistance)
4.Signed form by the patient himself or, by caregivers if the patient is not capable to fill, date and sign the form due to fine motor function difficulties..
5.Possible or probable PSP-R according to MDS criteria 2017(Hoglinger et al., Mov Disorder, 2017).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Number of patients reaching the optimal threshold of recordings during the recording periods defined in the protocol.
Number of patients reaching the optimal threshold of recordings during the recording periods defined in the protocol (supposed optimal threshold for analysis) at baseline, Month 4, Month 8, Month 12 and Month 16.
Time frame: 16 months
French Usability score (F-SUS) at Month 4 and at the end of the study
Usability score at Month 4 and Month 16. The System Usability Scale is a 10-item questionnaire . It is a simple tool to measure the usability of an interactive system and it is widely used. For each item, the user is asked to express their level of agreement or disagreement from 1 (strongly disagree) and 5 (strongly agree).
Time frame: 16 months
Change from baseline in the total wearing time at months 4, 8, 12, and 16.
Change from baseline in the total wearing time at months 4, 8, 12, and 16.
Time frame: 16 months
Reproducibility of Syde® digital endpoints for each recording period timepoint
Reproducibility of Syde® digital endpoints assessed by the ICC (Intra-Class Correlation) and Bland and Altman analysis for each recording period timepoint (baseline, 4 months, 8 months, 12 months, and 16 months)
Time frame: 16 months
Correlation between Syde® digital endpoints and 2-minute walk test (2MWT)
Correlation at baseline and at different timepoints between Syde® digital endpoints and 2MWT
Time frame: 16 months
Correlation between Syde® digital endpoints and 10-meter walk test (10MWT)
Correlation at baseline and at different timepoints between Syde® digital endpoints and 10MWT
Time frame: 16 months
Correlation between Syde® digital endpoints and Timed Up and Go (TUG)
Correlation at baseline and at different timepoints between Syde® digital endpoints and TUG
Time frame: 16 months
Correlation between Syde® digital endpoints and falls reported by the participants
Correlation at baseline and at different timepoints between Syde® digital endpoints and falls reported by the participants
Time frame: 16 months
Correlation between Syde® digital endpoints and Progressive Supranuclear Palsy Rating Scale (PSP-RS)
Correlation at baseline and at different timepoints between Syde® digital endpoints and PSP-RS
Time frame: 16 months
Correlation between Syde® digital endpoints and Progressive Supranuclear Palsy Clinical Deficits Scale (PSP-CDS)
Correlation at baseline and at different timepoints between Syde® digital endpoints and PSP-CDS
Time frame: 16 months
Correlation between Syde® digital endpoints and Montreal Cognitive Assessment (MoCA)
Correlation at baseline and at different timepoints between Syde® digital endpoints and MoCA
Time frame: 16 months
Longitudinal change in Syde® digital endpoints. The Syde® digital endpoints will include the SV95C (Stride Velocity 95th centile)
Change from baseline in Syde® digital endpoints at 4, 8, 12 and 16 months. The Syde® digital endpoints will include the SV95C (Stride Velocity 95th centile)
Time frame: 16 months
Start is estimated for Jan 2027; primary completion for Nov 2028, 22 months later.
Of 37 observational studies under Supranuclear Palsy, Progressive, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 54. This study's planned 22 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: start May 2026 → Jan 2027, primary completion Mar 2028 → Nov 2028 and completion Mar 2028 → Nov 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Supranuclear Palsy, Progressive →
SYSNAV